The European Medicines Agency unveiled several changes to the organization, including a new structure and visual identity.
The European Medicines Agency (EMEA) unveiled several changes to the organization on Dec. 8, 2009, including a new structure and visual identity, according to an agency press release.
One primary structural change involves integrating human pre- and postauthorization activities into one unit “to guarantee seamless lifecycle-management of medicines,” says the release. Also, a group will be dedicated to the management of product data and documentation to help improve the efficiency of data-management processes throughout the agency.
This is the second time EMEA has undergone restructuring. Since its establishment in 1995, the agency’s “responsibilities and tasks have grown, giving it a stronger role in the protection of public and animal health in Europe,” according to the release. “All of this has been underpinned by the creation of additional scientific committees and advisory groups, which bring with them the need for enhanced coordination and support. Legislative proposals currently being considered by the European Parliament and Council are expected to bring further responsibilities to the Agency.”
As part of the agency’s new visual, or public, identity, EMEA will launch a new website in the coming months. The site is expected to be easier for the public to use and designed to meet readers’ needs. Also of note, from now on, EMEA will be known as EMA.
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
Drug Solutions Podcast: Gliding Through the Ins and Outs of the Pharma Supply Chain
November 14th 2023In this episode of the Drug Solutions podcast, Jill Murphy, former editor, speaks with Bourji Mourad, partnership director at ThermoSafe, about the supply chain in the pharmaceutical industry, specifically related to packaging, pharma air freight, and the pressure on suppliers with post-COVID-19 changes on delivery.
INTERPHEX 2025: Use of Walk-In Chambers for Bio/Pharma Development and Manufacturing
April 2nd 2025Sitting down with the PharmTech Group at INTERPHEX 2025, Christopher Murphy, director of Global Business Development and Service Customer Support at Environmental Specialties, discusses the design and critical role of walk-in chambers in the bio/pharmaceutical industry.